sorafenib has been researched along with sch 54292 in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (sch 54292) | Trials (sch 54292) | Recent Studies (post-2010) (sch 54292) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 7 | 0 | 2 |
| Protein | Taxonomy | sorafenib (IC50) | sch 54292 (IC50) |
|---|---|---|---|
| GTPase NRas | Homo sapiens (human) | 0.5 | |
| GTPase KRas | Homo sapiens (human) | 0.7 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Korzeniecki, C; Priefer, R | 1 |
1 review(s) available for sorafenib and sch 54292
| Article | Year |
|---|---|
Targeting KRAS mutant cancers by preventing signaling transduction in the MAPK pathway.
Topics: Humans; Models, Molecular; Molecular Structure; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Signal Transduction | 2021 |